EIF2A and acute lymphoblastic leukemia: Combination of PEG-ARG1 with cytarabine (Ara-C) or phospho-eIF2a signaling significantly prolonged the survival of mice bearing T-ALL, representing a potential treatment therapy for this high-risk subtype of leukemia (59).